Eliem Therapeutics (ELYM) Stock Chart & Stock Price History → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free ELYM Stock Alerts $7.71 +0.05 (+0.65%) (As of 05/31/2024 ET) Add Compare Share Share ChartStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Eliem Therapeutics Stock Price Performance5 Day Performance+0.65%1 Month Performance-8.10%3 Month Performance+186.62%6 Month Performance+195.40%Year-To-Date Performance+185.56%1 Year Performance+161.36% Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. ELYM Stock Chart for Sunday, June, 2, 2024 ELYM Chart by TradingView Eliem Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/31/2024$7.66$7.71+0.65%$8.30$7.5668,742 shs$224.28 million05/30/2024$7.67$7.66-0.13%$8.05$7.54116,513 shs$222.83 million05/29/2024$7.66$7.67+0.13%$8.07$7.4497,845 shs$223.12 million05/28/2024$7.41$7.66+3.37%$7.70$7.1986,516 shs$222.83 million05/27/2024$7.41$7.41$7.74$7.03210,900 shs$215.56 million05/24/2024$7.44$7.41-0.40%$7.65$7.03210,994 shs$215.56 million Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/23/2024$7.87$7.44-5.46%$8.30$7.3039,438 shs$216.43 million05/22/2024$7.84$7.87+0.38%$8.18$7.6068,148 shs$228.95 million05/21/2024$8.20$7.84-4.39%$8.18$7.6738,624 shs$228.07 million05/20/2024$8.25$8.20-0.61%$8.91$8.1456,621 shs$238.54 million05/17/2024$8.18$8.25+0.86%$8.61$7.76318,648 shs$228.69 million05/16/2024$7.99$8.18+2.38%$8.99$7.67134,900 shs$226.75 million05/15/2024$8.19$7.99-2.44%$8.50$7.86202,767 shs$221.48 million05/14/2024$8.41$8.19-2.62%$8.81$8.02163,456 shs$227.03 million05/13/2024$8.46$8.41-0.59%$9.19$8.22114,249 shs$233.13 million05/10/2024$8.95$8.46-5.47%$9.54$8.33167,770 shs$234.55 million05/09/2024$9.32$8.95-3.97%$10.23$8.84219,559 shs$248.13 million05/08/2024$10.20$9.32-8.63%$10.86$9.27304,666 shs$258.39 million05/07/2024$8.65$10.20+17.92%$10.34$8.44288,439 shs$282.79 million05/06/2024$10.16$8.65-14.82%$10.00$8.42404,781 shs$239.78 million05/03/2024$8.39$10.16+21.04%$11.55$8.401.48 million shs$281.50 million05/02/2024$7.57$8.39+10.83%$8.75$7.50385,669 shs$232.60 million05/01/2024$7.09$7.57+6.77%$7.73$6.66936,273 shs$209.84 million04/30/2024$5.02$7.09+41.24%$7.80$5.023.97 million shs$196.54 million04/29/2024$3.98$5.02+26.13%$5.89$4.011.59 million shs$139.15 million04/26/2024$3.39$3.98+17.40%$4.16$3.33580,061 shs$110.33 million04/25/2024$3.66$3.39-7.38%$3.80$3.35388,878 shs$93.97 million04/24/2024$3.75$3.66-2.40%$3.86$3.66113,513 shs$101.46 million04/23/2024$3.87$3.75-3.10%$4.16$3.7186,068 shs$103.95 million04/22/2024$3.85$3.87+0.52%$4.12$3.7495,362 shs$107.28 million04/19/2024$4.18$3.85-7.89%$4.44$3.68451,267 shs$106.72 million04/18/2024$4.43$4.18-5.64%$4.50$4.15208,796 shs$122.80 million04/17/2024$4.56$4.43-2.85%$4.73$4.40211,260 shs$122.80 million04/16/2024$4.75$4.56-4.00%$4.95$4.56217,705 shs$126.40 million04/15/2024$4.31$4.75+10.21%$5.18$4.33911,995 shs$131.67 million04/12/2024$4.58$4.31-5.90%$4.97$4.301.19 million shs$119.47 million04/11/2024$2.67$4.58+71.54%$4.75$3.9239.07 million shs$126.96 million04/10/2024$2.70$2.67-1.11%$2.88$2.6710,804 shs$74.01 million04/09/2024$2.70$2.70$2.75$2.652,484 shs$74.84 million04/08/2024$2.60$2.70+3.85%$2.74$2.604,737 shs$74.84 millionThe Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it.04/05/2024$2.79$2.60-6.81%$2.71$2.52116,758 shs$72.07 million04/04/2024$2.86$2.79-2.45%$2.89$2.67123,482 shs$77.34 million04/03/2024$2.81$2.86+1.78%$2.91$2.70122,798 shs$79.28 million04/02/2024$2.80$2.81+0.36%$2.95$2.708,340 shs$77.47 million04/01/2024$2.74$2.80+2.19%$2.82$2.693,314 shs$77.20 million03/29/2024$2.74$2.74$2.80$2.722,767 shs$75.55 million03/28/2024$2.76$2.74-0.72%$2.80$2.722,767 shs$75.54 million03/27/2024$2.71$2.76+1.85%$2.81$2.713,570 shs$76.09 million03/26/2024$2.82$2.71-3.90%$2.86$2.711,785 shs$74.72 million03/25/2024$2.81$2.82+0.36%$2.90$2.7314,700 shs$77.75 million03/22/2024$2.73$2.81+2.93%$2.93$2.703,755 shs$77.47 million03/21/2024$2.79$2.73-2.15%$2.80$2.727,851 shs$75.27 million03/20/2024$2.78$2.79+0.36%$2.88$2.774,836 shs$76.92 million03/19/2024$2.81$2.78-1.07%$2.90$2.6728,540 shs$76.65 million03/18/2024$2.70$2.81+4.07%$2.85$2.784,595 shs$77.47 million03/15/2024$2.79$2.70-3.23%$2.73$2.602,778 shs$74.44 million03/14/2024$2.82$2.79-1.06%$2.80$2.636,444 shs$76.93 million03/13/2024$2.54$2.82+11.02%$2.85$2.6522,721 shs$77.75 million03/12/2024$2.80$2.54-9.43%$2.81$2.545,430 shs$70.03 million03/11/2024$2.73$2.80+2.73%$2.84$2.802,690 shs$77.32 million03/08/2024$2.85$2.73-4.21%$2.84$2.721,714 shs$75.27 million03/07/2024$2.79$2.85+2.15%$2.88$2.734,231 shs$78.57 million03/06/2024$2.82$2.79-1.06%$2.85$2.765,846 shs$76.92 million03/05/2024$2.72$2.82+3.68%$2.89$2.7210,832 shs$77.76 million03/04/2024$2.69$2.72+1.12%$2.87$2.7211,280 shs$74.99 million03/01/2024$2.73$2.69-1.47%$2.75$2.67483 shs$74.16 million Related Companies: XBiotech Stock Price Chart Compugen Stock Price Chart Cue Biopharma Stock Price Chart Marinus Pharmaceuticals Stock Price Chart Biora Therapeutics Stock Price Chart MEI Pharma Stock Price Chart COMPASS Pathways Stock Price Chart Altimmune Stock Price Chart Immunome Stock Price Chart Ocular Therapeutix Stock Price Chart Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELYM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.